Pharmacogenetics of new oral anticoagulants

The review presents modern studies the effect of genetic polymorphisms on efficienty and safety therapy with new oral anticoagulants. Hepatic carboxylesterase encoded by CES1 gene P-glycoprotein ABCB1 affect dabigatran pharmacokinetics. role glucuronidation enzymes (UGT2B15, UGT1A9, UGT2B7) involved in active metabolism is poorly understood. An increase peak apixaban concentration was noted patients rs4148738 polymorphism gene. Polymorphisms rs776746 rs77674 CYP3A5 Asian thus increased bleeding risk. SULT1A1 sulfotransferase has yet to be studied. BCRP protein ABCG2 a studied but promising direction for pharmacokinetics apixaban. CYP3A4 cytochrome P450 system rivaroxaban metabolism, however, number devoted examining these genes limited. Thus, large are needed clarify clinical relevance genotyping target taking